Advertisement

Journal of Applied Genetics

, Volume 47, Issue 4, pp 365–375 | Cite as

Epigenetic diagnostics of cancer — the application of DNA methylation markers

  • Jaroslaw Paluszczak
  • Wanda Baer-Dubowska
Review Article

Abstract

In recent years it has become apparent that epigenetic events are potentially equally responsible for cancer initiation and progression as genetic abnormalities. DNA methylation is the main epigenetic modification in humans. Two DNA methylation lesions coexist in human neoplasms: hypermethylation of promoter regions of specific genes within a context of genomic hypomethylation. Aberrant methylation is found at early stages of carcinogenesis and distinct types of cancer exhibit specific patterns of methylation changes. Tumor specific DNA is readily obtainable from different clinical samples and methylation status analysis often permits sensitive disease detection. Methylation markers may also serve for prognostic and predictive purposes as they often reflect the metastatic potential and sensitivity to therapy. As current findings show a great potential of recently characterised methylation markers, more studies in the field are needed in the future. Large clinical studies of newly developed markers are especially needed. The review describes the diagnostic potential of DNA methylation markers.

Key words

cancer diagnostics DNA hypermethylation DNA hypomethylation epigenetics methylation markers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa J-P, 1998. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58: 5489–5494.PubMedGoogle Scholar
  2. Alaminos M, Davalos V, Cheung N-KV, Gerald WL, Esteller M, 2004. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 96: 1208–1219.CrossRefPubMedGoogle Scholar
  3. Anacleto C, Rossi B, Lopes A, Soares FA, Rocha JC, Caballero O, et al. 2005. Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer. Oncol Rep 13: 325–328.PubMedGoogle Scholar
  4. Anzola M, Cuevas N, Lopez-Martinez M, Martinez de Pancorbo M, Burgos JJ, 2004. Patterns of methylation profiles as diagnostic markers for multiple hepatocellular carcinomas. Scand J Gastroenetrol 39: 246–251.CrossRefGoogle Scholar
  5. Arnold CN, Goel A, Boland CR, 2003. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66–73.CrossRefPubMedGoogle Scholar
  6. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, et al. 2004. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 10: 5998–6005.CrossRefPubMedGoogle Scholar
  7. Baker EK, El-Osta A, 2003. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 290: 177–194.CrossRefPubMedGoogle Scholar
  8. Ballestar E, Esteller M, 2002. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23: 1103–1109.CrossRefPubMedGoogle Scholar
  9. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al.-Saleem T, et al. 2003. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 63: 8695–8699.PubMedGoogle Scholar
  10. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG, 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687–692.CrossRefPubMedGoogle Scholar
  11. Blan JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, et al. 2004. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68: 275–283.CrossRefGoogle Scholar
  12. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al. 2001. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528–3532.CrossRefPubMedGoogle Scholar
  13. Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, et al. 2002. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res 8: 3741–3746.PubMedGoogle Scholar
  14. Chang HW, Chow V, Lam KY, Wei WI, Yuen A, 2002. Loss of E-Cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 94: 386–392.CrossRefPubMedGoogle Scholar
  15. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. 2002. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 3669–3675.PubMedGoogle Scholar
  16. Chen W-D, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. 2005. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124–1132.CrossRefPubMedGoogle Scholar
  17. Chim CS, Liang R, Tam CY, Kwong YL, 2001. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 19: 2033–2040.PubMedGoogle Scholar
  18. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, et al. 2003. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys Res Commun 307: 52–63.CrossRefPubMedGoogle Scholar
  19. Cottrell SE, 2004. Molecular diagnostic applications of DNA methylation technology. Clin Biochem 37: 595–604.CrossRefPubMedGoogle Scholar
  20. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P, 2004a. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10: 1887–1893.CrossRefPubMedGoogle Scholar
  21. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P, 2004b. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10: 6189–6193.CrossRefPubMedGoogle Scholar
  22. Ehrlich M, 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400–5413.CrossRefPubMedGoogle Scholar
  23. Esteller M, 2005. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 205: 172–180.CrossRefPubMedGoogle Scholar
  24. Esteller M, Corn PG, Baylin SB, Herman JG, 2001. A gene hypermethylation profile of human cancer. Cancer Res 61: 3225–3229.PubMedGoogle Scholar
  25. Esteller M, Herman JG, 2004. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23: 1–8.CrossRefPubMedGoogle Scholar
  26. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, et al. 2005. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97: 273–282.CrossRefPubMedGoogle Scholar
  27. Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, et al, 2004. Methylated DNA collected by tampons — a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 13: 882–888.PubMedGoogle Scholar
  28. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. 2005. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65: 1141–1145.CrossRefPubMedGoogle Scholar
  29. Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, et al. 2005. Methylation discriminators in NSCLC identified by a microarray based approach. Int J Oncol 27: 105–111.PubMedGoogle Scholar
  30. Fujiwara K, Fijimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al. 2005. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11: 1219–1225.CrossRefPubMedGoogle Scholar
  31. Fulda S, Kuefer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K-M, 2001. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865–5877.CrossRefPubMedGoogle Scholar
  32. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R, 2004. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420–4426.CrossRefPubMedGoogle Scholar
  33. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, De Juan C, Sanchez-Pernaute A, Torres A, et al. 2004. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 24: 349–355.PubMedGoogle Scholar
  34. Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, et al. 2004. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 10: 7276–7283.CrossRefPubMedGoogle Scholar
  35. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, et al. 2004. Prognostic analysis of E-Cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10: 2784–2789.CrossRefPubMedGoogle Scholar
  36. Grunau C, Sanchez C, Ehrlich M, van der Bruggen P, Hindermann W, Rodriguez C, et al. 2005. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 43: 11–24.CrossRefPubMedGoogle Scholar
  37. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. 2004. Clinical trial substantiates the predictive value of O-6-methylaguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871–1874.CrossRefPubMedGoogle Scholar
  38. Henrique R, Jeronimo C, 2004. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46: 660–669.CrossRefPubMedGoogle Scholar
  39. Hoque MO, Begom S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. 2004. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64: 5511–5517.CrossRefPubMedGoogle Scholar
  40. House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, et al. 2003. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behaviour. J Gastrointest Surg 7: 1001–1014.CrossRefGoogle Scholar
  41. Itano O, Ueda M, Kikuchi K, Hashimoto O, Hayatsu S, Kawaguchi M, et al. 2002. Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 21: 789–797.CrossRefPubMedGoogle Scholar
  42. Jaenisch R, Bird A, 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl.): 245–254.CrossRefPubMedGoogle Scholar
  43. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. 2001. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659–1665.PubMedGoogle Scholar
  44. Jenuwein T, Allis CD, 2001. Translating the histone code. Science 293: 1074–1079.CrossRefPubMedGoogle Scholar
  45. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. 2004. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 10: 4010–4014.CrossRefPubMedGoogle Scholar
  46. Jones PA, Takai D, 2001. The role of DNA methylation in mammalian epigenetics. Science 293: 1068–1070.CrossRefPubMedGoogle Scholar
  47. Kawakami T, Okamoto K, Ogawa O, Okada Y, 2004. XIST unmethylated DNA fragments in male-derived plasma as a tumor marker for testicular cancer. Lancet 363: 40–42.CrossRefPubMedGoogle Scholar
  48. Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, et al. 2004. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer Cancer. 22: 2363–2370.Google Scholar
  49. Kim WJ, Vo QN, Shrivastav M, Lataxes TA, Brown KD, 2002. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21: 3864–3871.CrossRefPubMedGoogle Scholar
  50. Kimura N, Nagasaka T, Murakami J, Sasamoto H, Murakami M, Tanaka N, et al. 2005. Methylation profiles of genes utilizing newly developed CpG island methylation microarray on colorectal cancer patients. Nucleic Acids Res 33: e46.CrossRefPubMedGoogle Scholar
  51. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, et al. 2004. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 3: 16.CrossRefPubMedGoogle Scholar
  52. Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, et al. 2004. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10: 28–32.CrossRefPubMedGoogle Scholar
  53. Laird PW, 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253–266.CrossRefPubMedGoogle Scholar
  54. Laird PW, 2005. Cancer epigenetics. Hum Mol Genet 14: R65-R76.CrossRefPubMedGoogle Scholar
  55. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, et al. 2005. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 92: 2190–2194.CrossRefPubMedGoogle Scholar
  56. Levenson VV, 2004. DNA methylation biomarkers of cancer: moving toward clinical application. Pharmacogenomics 5: 699–707.CrossRefPubMedGoogle Scholar
  57. Lofton-Day C, Lesche R, 2003. DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig Dis 21: 299–308.CrossRefPubMedGoogle Scholar
  58. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C, 2005. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 5: 223–232.CrossRefPubMedGoogle Scholar
  59. Marchevsky AM, Tsou JA, Laird-Offringa IA, 2004. Classification of individual lung cancer cell lines based on DNA methylation markers. Use of linear discriminant analysis and artificial neural networks. JMolDiagn6: 28–36.Google Scholar
  60. Martens JWM, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, et al. 2005. Association of DNA methylation of phosphoserine amino-transferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65: 4101–4107.CrossRefPubMedGoogle Scholar
  61. Miyamoto K, Ushijima T, 2005. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35: 293–301.CrossRefPubMedGoogle Scholar
  62. Mueller HM, Widschwendter M, 2003. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn 3: 443–458.CrossRefGoogle Scholar
  63. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, et al. 2003. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 105: 491–493.CrossRefPubMedGoogle Scholar
  64. Olopade OI, Wei M, 2003. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3: 417–420.CrossRefPubMedGoogle Scholar
  65. Pakneshan P, Tetu B, Rabbani SA, 2004. Demethylation of urokinase promoter as a progostic marker in patients with breast carcinoma. Clin Cancer Res 10: 3035–3041.CrossRefPubMedGoogle Scholar
  66. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. 2000. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954–5958.PubMedGoogle Scholar
  67. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC, 2005. P-Cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869–5877.CrossRefPubMedGoogle Scholar
  68. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R, 2000. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039–6044.PubMedGoogle Scholar
  69. Roman J, Castillejo JA, Jimenez A, Bornstein R, Gonzalez MG, del Carmen Rodriguez M, et al. 2001. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br J Haematol 113: 329–338.CrossRefPubMedGoogle Scholar
  70. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, del Carmen Rodriguez M, et al. 2002. 5’CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291–2296.CrossRefPubMedGoogle Scholar
  71. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, et al. 2005. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11: 8321–8325.CrossRefPubMedGoogle Scholar
  72. Russo AL, Thiagalingam A, Pan H, Califano J, Cheng K-H, Ponte JF, et al. 2005. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 11: 2466–2470.CrossRefPubMedGoogle Scholar
  73. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, et al. 2004. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64: 1425–1430.CrossRefPubMedGoogle Scholar
  74. Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu B, Hsieh J-T, et al. 2003. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancer and its relationship to clinicopathological features. Clin Cancer Res 9: 6395–6400.PubMedGoogle Scholar
  75. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. 2003. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606–8613.PubMedGoogle Scholar
  76. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. 2005. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262–1266.CrossRefPubMedGoogle Scholar
  77. Siu LL, Chan JK, Wong KF, Choy C, Kwong YL, 2003. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 122: 70–77.CrossRefPubMedGoogle Scholar
  78. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D, 2004. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10: 5518–5522.CrossRefPubMedGoogle Scholar
  79. Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, et al. 2004. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10: 2284–2288.CrossRefPubMedGoogle Scholar
  80. Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, et al. 2005. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma and non-tumor lung. Lung Cancer 47: 193–204.CrossRefPubMedGoogle Scholar
  81. Ushijima T, 2005. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223–231.CrossRefPubMedGoogle Scholar
  82. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan Y-H, et al. 2004. Value ofp16 INK4α andRASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10: 6119–6125.CrossRefPubMedGoogle Scholar
  83. Widschendter A, Ivarssin L, Blassnig A, Mueller HM, Fiegl H, Wiedemair A, et al. 2004. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109: 163–166.CrossRefGoogle Scholar
  84. Widschwendter M, Siegmund KD, Mueller HM, Fiegl H, Marth C, Mueller-Holzner E, et al. 2004. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64: 3807–3813.CrossRefPubMedGoogle Scholar
  85. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P, 2001. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 276: 39990–40000.CrossRefPubMedGoogle Scholar

Copyright information

© Institute of Plant Genetics, Polish Academy of Sciences, Poznan 2006

Authors and Affiliations

  1. 1.Department of Pharmaceutical BiochemistryUniversity of Medical SciencesPoznańPoland

Personalised recommendations